Navigation Links
Extreme makeover: Stanford scientists explore new way to change cell's identity
Date:5/5/2009

STANFORD, Calif. Even cells aren't immune to peer pressure. Scientists at the Stanford University School of Medicine have now shown that skin cells can be coaxed to behave like muscle cells and muscle cells like skin cells solely by altering who they hang out with: the relative levels of the ingredients inside the cell.

The fickleness of the cells, and the relative ease with which they make the switch, provide a glimpse into the genetic reprogramming that must occur for a cell to become something it's not.

"We'd all like to understand what happens inside the black box," said Helen Blau, PhD, the Donald E. and Delia B. Baxter Professor and member of Stanford's Stem Cell Biology and Regenerative Medicine Institute. "These types of experiments will help us to identify the earliest regulators of reprogramming."

Harnessing these genetic makeovers will allow scientists to better understand how to induce specialized adult cells to revert to a stem-cell-like state in a process called induced pluripotency. These newly pluripotent, or iPS, cells, which can then be encouraged to branch out into a variety of other cell types, have shown increasing promise as possible therapies for disorders like diabetes. But Blau's experiments suggest an intriguing alternative to iPS: that of enticing specialized adult cells to move sideways from one developmental fate to another without requiring a dip into the stem cell pool.

Blau, who directs the Baxter Laboratory of Genetic Pharmacology at the medical school, is the senior author of the research, which is published in the May issue of the FASEB Journal. She and her laboratory members fused mouse muscle cells with human skin cells to create hybrids called heterokaryons. In heterokaryons, the nuclei of each cell type remains distinct, and the influence of one on the nature of the other can be clearly distinguished. They then examined the hybrids to see if they began to look and act more like
'/>"/>

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
2. A History of Philanthropy Made Green-certified Legend Homes an Easy Choice for Extreme Makeover: Home Edition
3. Which intervention would do the most to improve the health of the extreme poor?
4. 3-drug combination extremely promising as first-line therapy for multiple myeloma
5. Extreme Networks Provides Resilient Wired and Wireless Network to the UKs Basildon & Thurrock Hospital
6. Extreme obesity affects chances of kidney transplantation
7. New method enables design, production of extremely novel drugs
8. Extremely low dose CT coronary angiography shows promise in assessing cardiac function
9. Factors affecting survival, disability of extremely premature infants identified
10. Steno Superbug Genome Shows Extreme Drug Resistance
11. SheKnows Names Americas Most Extreme Mom for Mothers Day
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Vivakor Announces New Acquisition Strategy 2Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 1YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 2YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 3YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 4YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 5YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD AN AUSTRALIAN CANCER FOCUSED DEVELOPMENT COMPANY 14357 6U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 1U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 2U S FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U S Bridge to Transplant Clinical Trial 5241 3New Hampshire Rx Card Launching Statewide 5239 1New Hampshire Rx Card Launching Statewide 5239 2